for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

I-Mab ADR

IMAB.O

Latest Trade

37.84USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.30

 - 

47.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.84
Open
--
Volume
--
3M AVG Volume
5.56
Today's High
--
Today's Low
--
52 Week High
47.46
52 Week Low
9.30
Shares Out (MIL)
162.14
Market Cap (MIL)
2,616.80
Forward P/E
-196.92
Dividend (Yield %)
--

Latest Developments

More

I-Mab Says Selling Shareholders May Offer, From Time To Time, Up To 25.1 Million Ordinary Shares

Morphosys, I-Mab Gets FDA Clearance Of Ind Application For Mor210/Tj210 In Patients With Advanced Cancer

Morphosys, I-Mab Announce FDA Clearance For Mor210/Tj210 In Patients With Advanced Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About I-Mab ADR

I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

WILLOW HOUSE, Floor 4

SHANGHAI, SHA

201210

China

+86.21.60578000

http://www.i-mabbiopharma.com/en/

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.2K
EPS (USD)

2020(E)

0.013
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,144.80
Price To Book (MRQ)
8.27
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.06
LT Debt To Equity (MRQ)
4.06
Return on Investment (TTM)
-70.52
Return on Equity (TTM)
-58.81

Latest News

Latest News

BRIEF-I-Mab Says Abbvie Has A Right Of First Negotiation To In-License Further Development And Commercialization Of 2 Additional Lemzoparlimab-Based Bispecific Antibodies- Conf. Call

* SAYS POTENTIAL VALUE OF SUCH LICENSE OF THE 2 BISPECIFIC PROGRAMS IS A MINIMUM $1 BILLION IN UPFRONT AND MILESTONE PAYMENTS- CONF. CALL

AbbVie to develop and sell China-based I-Mab's cancer drug

U.S. drugmaker AbbVie Inc will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's cancer drug, the companies said on Friday.

AbbVie to develop, sell I-Mab's lead cancer drug

Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab's lead cancer drug, the companies said on Friday.

BRIEF-I-Mab And ABL Bio To Present Preclinical Data For Joint Bispecific Antibody Program

* I-MAB AND ABL BIO TO PRESENT PRECLINICAL DATA FOR JOINT BISPECIFIC ANTIBODY PROGRAM AT THE 2020 AMERICAN ASSOCIATION FOR CANCER RESEARCH VIRTUAL MEETING II Source text for Eikon: Further company coverage:

BRIEF-I-Mab Reports Interim Results From Study Of Potential COVID-19 Treatment

* I-MAB REPORTS INTERIM RESULTS FROM PART 1 STUDY FOR ANTI-GM-CSF ANTIBODY TJM2 TO TREAT COVID-19 PATIENTS WITH -CYTOKINE RELEASE SYNDROME

BRIEF-I-Mab, Genexine Report China NMPA Clearance For Phase 2 Glioblastoma Multiforme Clinical Trial

* I-MAB AND GENEXINE ANNOUNCE CHINA NMPA CLEARANCE FOR PHASE 2 CLINICAL TRIAL OF TJ107/HYLEUKIN-7™ IN GLIOBLASTOMA MULTIFORME

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up